ONTEGIMOD (Allosite Therapeutics)

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameONTEGIMOD (Allosite Therapeutics)
Drug Alias NameONT01ONT-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-M agonists
TargetsIntegrin alpha-M
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus NephritisCarcinoma, Pancreatic Ductal +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAllosite Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAllosite TherapeuticsWashington University School Of MedicineUniversity Of Texas Medical Branch
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicLupus NephritisCarcinoma, Pancreatic Ductal +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A